SHZ · 300406.SZ
Beijing Strong Biotechnologies, Inc.
CN¥12.46-CN¥0.04 (-0.32%)
Beijing Strong Biotechnologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 22.37% below the high.
Loading market information…
SHZ · 300463.SZ · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:04 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
Maccura Biotechnology Co.Ltd’s quoted price sits in the lower half of its reported 52-week range, 36.76% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Maccura Biotechnology Co.Ltd’s forward annual dividend is CN¥0.10 per share, paid annual. The forward yield is 1.16% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Maccura Biotechnology Co.Ltd’s next earnings report is currently expected on Apr 27, 2027, with estimated earnings per share of CN¥0.48. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Maccura Biotechnology Co.Ltd’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Maccura Biotechnology Co. Ltd. is an enterprise actively involved in the entire process of in vitro diagnostic (IVD) products, from their initial conceptualization and refinement (research and development) to mass production and market delivery. The company also extends related support services, catering to clientele within China and across global territories. Its diverse portfolio features immunoassay solutions, exemplified by chemiluminescence analyzers and their accompanying reagents. In the domain of clinical chemistry, Maccura furnishes reagents vital for evaluating a broad spectrum of physiological indicators, including hepatic and renal function, glucose metabolism, iron levels, specialized proteins, cardiac health, lipid profiles, and coagulation. Moreover, the firm supplies sophisticated clinical laboratory instrumentation, notably automatic hematology systems and both automated and semi-automated coagulation analyzers. The company's offerings further extend to include diagnostic tools for SARS-CoV-2 (COVID-19), such as nucleic acid detection kits and other related items. Additional products consist of glucometers, point-of-care testing (POCT) devices like fluorescence immunoassay analyzers and colloidal gold rapid test kits, molecular diagnostics (e.g., PCR kits), and a variety of pathology supplies. Maccura Biotechnology Co. Ltd. was established in 1994 and maintains its principal operations in Chengdu, China.
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:20 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q2 2025 |
|---|
| Jul 31, 2025 |
| CN¥0.02 |
| CN¥564.78M |
| Q1 2025 | Apr 28, 2025 | CN¥0.04 | CN¥510.00M |
|---|
| Q1 2025 | Apr 28, 2025 | -CN¥0.25-257.75% vs estimate | CN¥601.00M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥12.46-CN¥0.04 (-0.32%)
Beijing Strong Biotechnologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 22.37% below the high.
CN¥15.01-CN¥0.83 (-5.24%)
TINAVI Medical Technologies Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.33% below the high.
CN¥16.68+CN¥0.92 (+5.84%)
Guangxi LiuYao Group Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 15.07% below the high.
CN¥9.22+CN¥0.23 (+2.56%)
Truking Technology Limited’s quoted price sits in the lower half of its reported 52-week range, 32.65% below the high.
CN¥2.85-CN¥0.04 (-1.38%)
Hunan Er-Kang Pharmaceutical Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 44.23% below the high.
CN¥9.16-CN¥0.57 (-5.86%)
Shanghai Runda Medical Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 55.9% below the high.
CN¥8.19-CN¥0.08 (-0.97%)
Allmed Medical Products Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 45.03% below the high.
CN¥3.23-CN¥0.17 (-5.0%)
B-SOFT Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 53.79% below the high.
